257 related articles for article (PubMed ID: 24367637)
1. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.
Antonysamy S; Condon B; Druzina Z; Bonanno JB; Gheyi T; Zhang F; MacEwan I; Zhang A; Ashok S; Rodgers L; Russell M; Gately Luz J
PLoS One; 2013; 8(12):e84147. PubMed ID: 24367637
[TBL] [Abstract][Full Text] [Related]
2. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
Jiao L; Liu X
Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
[TBL] [Abstract][Full Text] [Related]
5. Structure, mechanism, and regulation of polycomb-repressive complex 2.
Moritz LE; Trievel RC
J Biol Chem; 2018 Sep; 293(36):13805-13814. PubMed ID: 28912274
[TBL] [Abstract][Full Text] [Related]
6. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
7. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
8. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
[TBL] [Abstract][Full Text] [Related]
9. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
10. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
[TBL] [Abstract][Full Text] [Related]
11. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
12. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
Hwang IJ; Park J; Seo SB
Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
[TBL] [Abstract][Full Text] [Related]
13. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
16. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
17. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
18. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
19. Regulatory interactions between RNA and polycomb repressive complex 2.
Cifuentes-Rojas C; Hernandez AJ; Sarma K; Lee JT
Mol Cell; 2014 Jul; 55(2):171-85. PubMed ID: 24882207
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-dependent lysine deprotonation in EZH2 catalysis.
Kipp DR; Quinn CM; Fortin PD
Biochemistry; 2013 Oct; 52(39):6866-78. PubMed ID: 24000826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]